RRM2 and prostate carcinoma: Our mechanistic studies suggest that Bcl‐xL, Bim, CHK1, c‐Myc, Mcl‐1, RRM1, RRM2 and Wee1 play a role in the antitumour activity of CUDC‐907 against prostate cancer (Figure 6H).